FibroGen, Inc. Announces Investigational Anti-CTGF Therapeutic, FG-3019, Reduces Tumor Growth And Metastasis In Preclinical Models Of Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--June 22, 2006--FibroGen, Inc., today announced the publication of two studies demonstrating that connective tissue growth factor (CTGF) plays a causative role in pancreatic cancer and that FG-3019, the Company's fully human monoclonal antibody against CTGF, blocks tumor growth and metastases in preclinical models of pancreatic cancer. The studies were published in the May 22 issue of Molecular Cancer Therapeutics(1) and the June 1 issue of Cancer Research(2).